Results of the Phase 3 Study of Lenalidomide Versus Placebo As Maintenance Therapy Following Second-Line Treatment for Patients with Chronic Lymphocytic Leukemia (the CONTINUUM Trial)

被引：4
|
作者：
Foa, Robin [1 ]
Schuh, Anna [2 ]
Zaritskey, Andrey [3 ]
Semochkin, Sergey [4 ]
Simpson, David [5 ]
Egyed, Miklos [6 ]
Vokurka, Samuel [7 ]
Kassis, Jeannine [8 ]
Zhang, Jennie [9 ]
Purse, Brendan [9 ]
Chanan-Khan, Asher A. [10 ]
机构：
[1] Univ Sapienza, Policlin Umberto 1, Rome, Italy
[2] Univ Oxford, Oxford, England
[3] St Petersburg State Med Univ, St Petersburg, Russia
[4] Pirogov Russian Natl Res Med Univ, Moscow, Russia
[5] North Shore Hosp, Auckland, New Zealand
[6] Kaposi Mor Teaching Hosp, Dept Internal Med, Kaposvar, Hungary
[7] Univ Hosp Plzen, Plzen, Czech Republic
[8] Hop Maison Neuve Rosemont, Montreal, PQ, Canada
[9] Celgene Corp, Summit, NJ USA
[10] Mayo Clin, Div Hematol, Jacksonville, FL USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.230.230
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
230
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)
    Chanan-Khan, A.
    Egyed, M.
    Robak, T.
    Martinelli de Oliveira, F. A.
    Echeveste, M. A.
    Dolan, S.
    Desjardins, P.
    Blonski, J. Z.
    Mei, J.
    Golany, N.
    Zhang, J.
    Gribben, J. G.
    LEUKEMIA, 2017, 31 (05) : 1240 - 1243
  • [2] Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)
    A Chanan-Khan
    M Egyed
    T Robak
    F A Martinelli de Oliveira
    M A Echeveste
    S Dolan
    P Desjardins
    J Z Blonski
    J Mei
    N Golany
    J Zhang
    J G Gribben
    Leukemia, 2017, 31 : 1240 - 1243
  • [3] Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial
    Chanan-Khan, Asher A.
    Zaritskey, Andrey
    Egyed, Miklos
    Vokurka, Samuel
    Semochkin, Sergey
    Schuh, Anna
    Kassis, Jeannine
    Simpson, David
    Zhang, Jennie
    Purse, Brendan
    Foa, Robin
    LANCET HAEMATOLOGY, 2017, 4 (11): : E534 - E543
  • [4] Combination Therapy with Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial
    Ferrajoli, Alessandra
    O'Brien, Susan
    Wierda, William G.
    Faderl, Stefan
    Badoux, Xavier
    Estrov, Zeev
    Schlette, Ellen
    Smith, Susan C.
    Ayala, Ana B.
    Falchi, Lorenzo
    Calin, Steliana
    Kantarjian, Hagop M.
    Keating, Michael J.
    BLOOD, 2011, 118 (21) : 780 - 780
  • [5] Bendamustine vs. fludarabine as second-line treatment for patients with chronic lymphocytic leukemia - First interim results of a randomized study
    Niederle, N.
    Balleisen, L.
    Heit, W.
    Knauf, W.
    Weiss, J.
    Freier, W.
    Ibach, S.
    Eimermacher, H.
    ANNALS OF ONCOLOGY, 2008, 19 : 194 - 194
  • [6] BUDGET IMPACT ANALYSIS FOR THE FIRST-LINE AND SECOND-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
    Lachaine, J.
    Kouroukis, C. T.
    VALUE IN HEALTH, 2016, 19 (03) : A244 - A245
  • [7] Bosutinib as Third-Line Treatment for Chronic Phase Chronic Myeloid Leukemia Following Failure of Second-Line Therapy with Dasatinib or Nilotinib
    Khoury, H. Jean
    Kim, Dong-Wook
    Zaritskey, Andrey
    Gambacorti-Passerini, Carlo
    Hochhaus, Andreas
    Navarro, Juan
    Rapoport, Aaron P.
    Dorlhiac-Llacer, Pedro Enrique
    Zanichelli, Maria
    Kelly, Virginia
    Besson, Nadine
    McMullan, Trevor
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    BLOOD, 2010, 116 (21) : 391 - 391
  • [8] A phase II study of lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia
    Badoux, X.
    Wierda, W. G.
    O'Brien, S. M.
    Faderl, S.
    Estrov, Z.
    Yerrow, K. A.
    Keating, M. J.
    Ferrajoli, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Nilotinib As Second-Line Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase: Thailand Experience
    Chansung, Kanchana
    Sirijerachai, Chittima
    Lekhakula, Arnuparp
    Viboonjuntra, Pongtep
    Niparuck, Pimjai
    Pauvilai, Teeraya
    Numbenjapon, Tontanai
    Bunworasate, Udomsak
    Nawarawong, Weerasak
    Tantiworawit, Adisak
    Suwanban, Tawatchai
    Jootar, Saengsuree
    BLOOD, 2016, 128 (22)
  • [10] Combination of Ofatumumab and Lenalidomide In Patients with Relapsed Chronic Lymphocytic Leukemia: Initial Results of a Phase II Trial
    Badoux, Xavier
    O'Brien, Susan
    Wierda, William G.
    Faderl, Stefan
    Estrov, Zeev
    Yerrow, Kimberly
    Kantarjian, Hagop M.
    Keating, Michael J.
    Ferrajoli, Alessandra
    BLOOD, 2010, 116 (21) : 1023 - 1024
12345